Medicines Manufacturing Industry

Lord Patel Excerpts

Monday 27th February 2023 Lords Chamber

[Lord Parkinson of Whitley Bay (Con)]

I certainly shall, and through the creation of the Department for Science, Innovation and Technology, the point my noble friend makes is highlighted. This is an area where the UK has a globally unique offer, because we have already established a network of medicines manufacturing innovation centres which the industry can use to develop its own technologies, giving it a competitive edge, so the point he raises is important.

[Lord Patel (CB)]

My Lords, although I agree with the comments made by the noble Lords, Lord Hunt of Kings Heath and Lord Clement-Jones, also affecting the manufacture and development of medicines in the United Kingdom now is our ability to conduct clinical trials, particularly phase 3 trials. We are good at starting phase 1 trials but by the time it comes to phase 3, not enough patients have been recruited and so the commercial trials come to an end. That means that we are not developing new medicines for cancers, cardiac disease and rare diseases. We need much more co-ordination from the Government, from the regulatory authorities for medicine and the ethics research authority, and from integrated care boards and trusts, so that the recruitment of patients continues at phase 3.

[Lord Parkinson of Whitley Bay (Con)]

The noble Lord makes an important point. With the change in regulation following our departure from the European Union, we have further freedom to act in this area. It is important that we continue to seize those opportunities and ensure that we are at the cutting edge of scientific exploration. I will refer his points back to the department.